momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (3784)	1/26/2006 11:34:02 AM
From: scaram(o)uche	Read Replies (1) of 12215

Anti-idiotype projects have been around forever for B cell lymphoma. The first was at Idec, the first example of a patient-specific vaccine that was shown to be impractical....... was therefore rolled into "Specifid" or something like that. Also impractical, due to (1) limited coverage of primaries and (2) idiotype hide and seek. It's the primary reason that Idec was managed into the ground......... within weeks of bankruptcy before Genentech came knocking. Large Scale had an anti-id project, and I know that Tuck was trying to keep track of competitive projects. If I started out to do things the old way, I might contact scientists at the B lymphoma companies, and try to get dirt on the concept that idiotypes are relatively invariant in a given mantle cell patient.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next